^
Association details:
| Biomarker: | FGFR2 N549K |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Published date:
11/01/2020
Excerpt:
Across all tumor types studied, futibatinib inhibited the growth of cell lines with various FGFR genomic aberrations, but not of cell lines that did not harbor such aberrations....These FGFR aberrations included FGFR1/2 amplifications (breast cancer), FGFR1 amplifications (lung cancer), FGFR2 amplifications (gastric cancer), FGFR2 point mutations (endometrial cancer), FGFR3 fusions (bladder cancer), and FGFR3 translocations (multiple myeloma; Table 1...).
DOI:
10.1158/0008-5472.CAN-19-2568
Source:
Title:
Abstract 659: Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors
Published date:
05/15/2020
Excerpt:
Human endometrial FGFR2-N549K-mutated AN3CA cancer cells were treated with futibatinib plus either everolimus or MK2206 or with each agent alone…In ANC3A cells, the combination of futibatinib with MK2206 inhibited AKT phosphorylation; futibatinib plus either MK2206 or everolimus inhibited mTOR phosphorylation to a greater degree than monotherapy...The combination of futibatinib plus a PI3K pathway inhibitor resulted in synergistic antitumor effects.
Secondary therapy:
everolimus
DOI:
10.1158/1538-7445.AM2020-659
